

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Heidi Lopez de Diego et al.	Confirmation No.:	6471
Serial No.:	10/568,572	Group Art Unit:	1614
Filed:	August 14, 2006	Examiner:	TBA
For:	Succinate and Malonate Salts of [Trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine] and Use as a Medicament		

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Date: February 21, 2008

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir/Madame:

In order to comply with the duty of disclosure under 37 C.F.R. § 1.56, transmitted herewith is a Supplemental Information Disclosure Statement (SIDS) in connection with the above-identified patent application. This SIDS complies with the requirements under 37 C.F.R. § 1.98 and is being submitted pursuant to 37 C.F.R. § 1.97(b), wherein the SIDS is being offered before the mailing date of a first Office Action on the merits for the patent application.

Accordingly, Applicants believe no fee is required for submission of this SIDS. However, the Commissioner is hereby authorized to charge any deficiency in fees, or credit overpayment of the same, to Deposit Account No. 503201.

Further, the Examiner's attention is kindly directed to the documents identified on the attached PTO/SB/08 Form(s). Copies of the U.S. Patents and/or Patent Application Publications are not required pursuant to 37 C.F.R. § 1.98 and, therefore, have not been provided in connection with this submission if U.S. Patents and/or Patent Application Publications have been cited on the attached PTO/SB/08 Form(s). A copy of the non-patent literature document Cite No. 5 has not been provided because of its voluminous nature and likely availability to the Examiner; however, if the Examiner deems a copy should be provided, Applicants will make all reasonable efforts to provide one. Copies of all other references have been provided.

It is respectfully requested that these references be fully considered during the examination of this application and printed on any patent which may issue thereon; accordingly, Applicants kindly request that a copy of the PTO/SB/08 Form(s), as considered and initialed by the Examiner, be returned with the next office communication.

An early and favorable action is respectfully requested.

Respectfully submitted,

/Margaret M. Buck, Reg. No. 54,010/

Margaret M. Buck
Registration No. 54,010

Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
(201) 261-1331 Ext. 790